Collaboration
CLC bio Developing Molecular Diagnostics Platform
CLC bio, AROS Applied Biotechnology, F. Hoffmann-La Roche, and Aarhus University Hospital - the Institute of Pathology and the Research Unit for Molecular Medicine, announced a collaboration to develop a solution for large scale use of formalin fixed, paraffin embedded (FFPE) tissue in molecular analyses. The project goal is to develop a complete platform for selecting appropriate FFPE samples, choosing the optimal sequencing technology, and subsequently assembling and analyzing the high-...
European Collaborative Research to Develop Lab-on-a-Chip System for Cancer Diagnosis
At the Engineering in Medicine and Biology Conference in Buenos Aires, Argentina, the Interuniversity Microelectronics Centre (IMEC) and its project partners announced the launch of the European Seventh Framework Project, MIRACLE. The MIRACLE project aims at developing an operational lab-on-a-chip for the isolation and detection of circulating and disseminated tumor cells (CTCs and DTCs) in blood. The new lab-on-a- chip is an essential step toward faster and cost-efficient diagnosis of cancer....
NEC, SomaLogic Enter Agreement
NEC Corp. (NEC) and SomaLogic Inc. announced that they have signed an agreement to explore aptamer-related businesses in the life sciences and healthcare markets. In addition, NEC announced that it has made an equity investment in SomaLogic in support of a long-term strategic relationship between the two companies. The agreement establishes a framework for the two companies to develop and implement applications within NEC’s cloud-based services platform to enhance SomaLogic’s...
Alverix, BD to Develop Next-Generation POC Systems
As consumers begin to take greater ownership of their own healthcare, there is a growing demand for accessibility to diagnostic testing. Alverix Inc. and BD are on the cutting edge of this trend and today announced an agreement to produce assay systems at the point-of-care (POC) that will improve infectious disease diagnoses. When combined with existing diagnostic tests, or with assays currently being developed, Alverix’s devices enable central laboratory quality results to be realized in...
BioServe, NGC Medical SpA Launch BioServe-Europe
BioServe and NGC Medical SpA announced the opening of BioServe-Europe. Based in Milan, Italy BioServe-Europe provides the European life science research industry with a comprehensive range of molecular services, including the processing of new personal genetic tests, high-throughput genotyping, and DNA and RNA extractions. In addition, BioServe-Europe distributes biospecimens from its Global BioRepository and biobank partner network, as well as samples sourced from within the EU. "The...
Pathwork Diagnostics Partners with Novartis to Discover Molecular Diagnostics for Cancer
Pathwork Diagnostics Inc. announced that it has entered into a research collaboration with Novartis. The parties intend to discover clinically meaningful biomarker signatures that can serve as the basis for diagnostics across a range of cancer types. Under the terms of the agreement, both parties have rights to develop and commercialize the diagnostic products. Financial terms were not disclosed. “There is no question that the future of cancer treatment will require and depend on...
GE Launches Study to Improve Diagnosis of Early Stage Colon Cancer
A team of scientists at GE Global Research, the technology development arm for GE has launched a study with Memorial Sloan-Kettering Cancer Center (MSKCC) to better understand the early stages of colon cancer. The goal is to yield new insights that improve treatment selection and outcomes for cancer patients in the future. One of the primary issues in cancer diagnosis today is the limited amount of molecular information pathologists have about a particular cancer. At the time of diagnosis,...
ARUP Laboratories To Offer deCODE Prostate Cancer Test
deCODE genetics and ARUP Laboratories announced a partnership through which ARUP will offer deCODE’s DNA-based prostate cancer risk assessment test to its clients nationwide. Under the terms of the non-exclusive agreement, ARUP will integrate deCODE ProstateCancer into the portfolio of tests it offers to leading academic medical centers, public and private healthcare providers, and major hospitals across the United States. ARUP’s clients will order the test, submit samples and...
Thermo Fisher Scientific, Intrinsic Bioprobes Announce Alliance to Develop Mass Spectrometric Immunoassay
Thermo Fisher Scientific Inc. and Intrinsic Bioprobes Inc. (IBI) announced an alliance to codevelop and market a mass spectrometry solution that will enable researchers to perform quantitative, high-throughput, high-resolution protein biomarker assays. The solution couples the specificity ofimmunoenrichment with the sensitivity and quantitative capability of mass spectrometry to provide researchers with a more complete, higher-resolution view of the proteome. Initially, via an exclusive...
Roche, IBM Collaborate on Nanopore-Based DNA Sequencing Technology
Roche and IBM announced an agreement to develop a nanopore-based sequencer that will directly read and decode human DNA quickly and efficiently. Focused on advancing IBM’s recently published “DNA Transistor” technology, the collaboration will take advantage of IBM’s leadership in microelectronics, information technology and computational biology and Roche’s expertise in medical diagnostics and genome sequencing. The novel technology, developed by IBM Research,...